Entrada TherapeuticsTRDA -1.06%26 Net Debt Paydown Yield % is 2.92% as of Jul. 08, 2026. GuruFocus rates TRDA with a GF Score™ of 26/100 and a GF Value™ of $0.98 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,157 Biotechnology companies, Entrada Therapeutics ranks better than 84.36% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Entrada Therapeutics's Net Debt Paydown Yield % was 2.92%.
Entrada Therapeutics (NAS:TRDA) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Entrada Therapeutics Net Debt Paydown Yield % Related Terms
Entrada Therapeutics Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Entrada Therapeutics's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entrada Therapeutics Net Debt Paydown Yield % Chart
TRDA vs NMRA, MGNX, CNXU: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Entrada Therapeutics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entrada Therapeutics Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Entrada Therapeutics's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 2.92% mean?
Entrada Therapeutics (TRDA) has a Net Debt Paydown Yield % of 2.92% as of Jul. 08, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Entrada Therapeutics and its competitors. According to the industry distribution chart, Entrada Therapeutics ranks #181 out of 1157 companies in the Biotechnology industry, placing it in the top 15.6%.
Is Entrada Therapeutics' Net Debt Paydown Yield % too high?
Entrada Therapeutics' current Net Debt Paydown Yield % is 2.92%. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. Entrada Therapeutics' value of 2.92% is 9633.3% above this industry median. Based on the distribution chart, Entrada Therapeutics ranks #181 out of 1157 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Entrada Therapeutics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entrada Therapeutics' Net Debt Paydown Yield % compare to NMRA and MGNX?
According to the Biotechnology industry distribution chart, Entrada Therapeutics ranks #181 out of 1157 companies for Net Debt Paydown Yield %. This places Entrada Therapeutics in the top 16% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.03. Entrada Therapeutics' value of 2.92% is 9633.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entrada Therapeutics's current Net Debt Paydown Yield % of 2.92% is 9633.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Entrada Therapeutics and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entrada Therapeutics's current Net Debt Paydown Yield % is 2.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entrada Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.98, compared to a current price of $7.45 — trading 660.2% above its estimated fair value. The current Net Debt Paydown Yield % is 2.92% and 9633.3% above the Biotechnology industry median of 0.03. Entrada Therapeutics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current Net Debt Paydown Yield % is 2.92% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Entrada Therapeutics (TRDA) Overvalued in 2026?
Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued.
The current stock price of $7.45 is trading 660.2% above its estimated GF Value™ of $0.98.
GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.
Key valuation signals for TRDA:
Net Debt Paydown Yield %: 2.92%
GF Value™: $0.98 vs. price of $7.45 (660.2% above fair value)
Industry Position: 9633.3% above the Biotechnology median (#181 of 1157)
No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
26GF Score
Get the complete analysis for TRDA
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRDA has been successfully added to your 
